Protalix Biotherapeutics Inc - ESG Rating & Company Profile powered by AI
If you are employed by Protalix Biotherapeutics Inc and you wish to licence your Sustainability aseessment, please get in touch. This dashboard includes a questions and answers table for Protalix Biotherapeutics Inc. The Disclosure score covers seventeen UN SDGs including: 'Zero Hunger', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'.
Protalix Biotherapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 1.6 and governance score of 2.0.
1.2
Low ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1725478325797)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
1755 | Trimurthi Ltd | 1.3 | Low |
1779 | Protalix Biotherapeutics Inc | 1.2 | Low |
1779 | Cell Biotech Co Ltd | 1.2 | Low |
1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1725478325797)
Frequently Asked Questions
Does Protalix Biotherapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Protalix Biotherapeutics Inc disclose current and historical energy intensity?
Does Protalix Biotherapeutics Inc report the average age of the workforce?
Does Protalix Biotherapeutics Inc reference operational or capital allocation in relation to climate change?
Does Protalix Biotherapeutics Inc disclose its ethnicity pay gap?
Does Protalix Biotherapeutics Inc disclose cybersecurity risks?
Does Protalix Biotherapeutics Inc offer flexible work?
Does Protalix Biotherapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Protalix Biotherapeutics Inc disclose the number of employees in R&D functions?
Does Protalix Biotherapeutics Inc conduct supply chain audits?
Does Protalix Biotherapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Protalix Biotherapeutics Inc conduct 360 degree staff reviews?
Does Protalix Biotherapeutics Inc disclose the individual responsible for D&I?
Does Protalix Biotherapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Protalix Biotherapeutics Inc disclose current and / or historical scope 2 emissions?
Does Protalix Biotherapeutics Inc disclose water use targets?
Does Protalix Biotherapeutics Inc have careers partnerships with academic institutions?
Did Protalix Biotherapeutics Inc have a product recall in the last two years?
Does Protalix Biotherapeutics Inc disclose incidents of discrimination?
Does Protalix Biotherapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Protalix Biotherapeutics Inc issued a profit warning in the past 24 months?
Does Protalix Biotherapeutics Inc disclose parental leave metrics?
Does Protalix Biotherapeutics Inc disclose climate scenario or pathway analysis?
Does Protalix Biotherapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Protalix Biotherapeutics Inc disclose the pay ratio of women to men?
Does Protalix Biotherapeutics Inc support suppliers with sustainability related research and development?
Does Protalix Biotherapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Protalix Biotherapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Protalix Biotherapeutics Inc involved in embryonic stem cell research?
Does Protalix Biotherapeutics Inc disclose GHG and Air Emissions intensity?
Does Protalix Biotherapeutics Inc disclose its waste policy?
Does Protalix Biotherapeutics Inc report according to TCFD requirements?
Does Protalix Biotherapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Protalix Biotherapeutics Inc disclose energy use targets?
Does Protalix Biotherapeutics Inc disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Protalix Biotherapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Protalix Biotherapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.